Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA
暂无分享,去创建一个
S. Nelson | C. James | J. Heath | T. Cloughesy | P. Mischel | P. N. Rao | W. Cavenee | F. Furnari | H. Kornblum | A. Eskin | A. Paucar | J. Mottahedeh | T. Koga | Shaojun Zhu | M. Ohashi | Kiwook Hwang | J. Wykosky | Huijun Yang | Kenta Masui | G. Gomez | Koppany Visnyei | Rachel Reed | B. Gini | Jun Wang | D. Nathanson | A. A. Paucar | Tomoyuki Koga | P. Rao | Ascia Eskin | C. James
[1] D. Haussler,et al. The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.
[2] David Haussler,et al. Double minute chromosomes in glioblastoma multiforme are revealed by precise reconstruction of oncogenic amplicons. , 2013, Cancer research.
[3] Robert A. Weinberg,et al. Poised Chromatin at the ZEB1 Promoter Enables Breast Cancer Cell Plasticity and Enhances Tumorigenicity , 2013, Cell.
[4] J. Pollack,et al. EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms , 2013, Oncogene.
[5] K. Kinzler,et al. Cancer Genome Landscapes , 2013, Science.
[6] W. Sellers,et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance , 2013, Nature.
[7] Paul S Mischel,et al. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. , 2012, Cancer discovery.
[8] M. Glickman,et al. Converting Cancer Therapies into Cures: Lessons from Infectious Diseases , 2012, Cell.
[9] Levi A Garraway,et al. Circumventing cancer drug resistance in the era of personalized medicine. , 2012, Cancer discovery.
[10] Guy S. Salvesen,et al. SnapShot: Caspases , 2011, Cell.
[11] W. Cavenee,et al. Heterogeneity maintenance in glioblastoma: a social network. , 2011, Cancer research.
[12] Yoshitaka Narita,et al. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. , 2010, Genes & development.
[13] Hong Wu,et al. A microfluidic platform for systems pathology: multiparameter single-cell signaling measurements of clinical brain tumor specimens. , 2010, Cancer research.
[14] P. Jänne,et al. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor , 2010, Oncogene.
[15] R. McLendon,et al. Robust Detection of EGFR Copy Number Changes and EGFR Variant III: Technical Aspects and Relevance for Glioma Diagnostics , 2009, Brain pathology.
[16] N. Shimizu. Extrachromosomal Double Minutes and Chromosomal Homogeneously Staining Regions as Probes for Chromosome Research , 2009, Cytogenetic and Genome Research.
[17] R. Stupp,et al. Epidermal Growth Factor Receptor Inhibitors in Neuro-oncology: Hopes and Disappointments , 2008, Clinical Cancer Research.
[18] C. James,et al. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel , 2007, Molecular Cancer Therapeutics.
[19] W. Cavenee,et al. Immunohistochemical analysis of the mutant epidermal growth factor, ΔEGFR, in glioblastoma , 2006, Brain Tumor Pathology.
[20] Koji Yoshimoto,et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.
[21] C. James,et al. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. , 2005, Neuro-oncology.
[22] David J. Yang,et al. Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients , 2005, Clinical Cancer Research.
[23] F. Apiou,et al. Molecular structure of double-minute chromosomes bearing amplified copies of the epidermal growth factor receptor gene in gliomas. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[24] Caterina Giannini,et al. Immunohistochemical Detection of EGFRvIII in High Malignancy Grade Astrocytomas and Evaluation of Prognostic Significance , 2004, Journal of neuropathology and experimental neurology.
[25] Daniel H. Geschwind,et al. Cancerous stem cells can arise from pediatric brain tumors , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[26] P. Solal-Céligny. Rituximab as first-line monotherapy in low-grade follicular lymphoma with a low tumor burden. , 1991, Anti-cancer drugs.
[27] C. James,et al. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. , 2000, Cancer research.
[28] R. McLendon,et al. Tumor antigens in astrocytic gliomas , 1995, Glia.
[29] H. Fujita. [Anticancer drugs]. , 1995, Nihon rinsho. Japanese journal of clinical medicine.
[30] G. Wahl,et al. Elimination of extrachromosomally amplified MYC genes from human tumor cells reduces their tumorigenicity. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[31] P. Humphrey,et al. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. , 1990, Cancer research.
[32] P. Humphrey,et al. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[33] R T Schimke,et al. Loss and stabilization of amplified dihydrofolate reductase genes in mouse sarcoma S-180 cell lines , 1981, Molecular and cellular biology.
[34] D. Haber,et al. Unstable amplification of an altered dihydrofolate reductase gene associated with double-minute chromosomes , 1981, Cell.
[35] R T Schimke,et al. Gene amplification and drug resistance in cultured murine cells. , 1978, Science.